← Pharmacy curriculum
Module 18010 lessonsRxPrep 2023 Chapter 24, reconciled with current DailyMed labeling for fluconazole, itraconazole, voriconazole, posaconazole, isavuconazonium, and oral ketoconazole, plus current IDSA guidance

Triazole Antifungal Pharmacology

Master the azole target, agent-specific spectrum, formulation-dependent exposure, nonlinear pharmacokinetics, therapeutic monitoring, interaction management, and safe clinical transitions.

01

Connect azole structure to fungal CYP51 inhibition, selectivity, and resistance.

02

Distinguish yeast, mold, endemic-fungus, syndrome, and compartment roles across agents.

03

Apply fluconazole oral reliability, renal elimination, species limits, and safety principles.

04

Prevent itraconazole formulation, administration, cardiac, and exposure errors.

05

Use voriconazole nonlinear pharmacokinetics, variability, monitoring, and toxicity surveillance.

06

Select and administer the correct posaconazole formulation without unsafe substitution.

07

Translate isavuconazonium prodrug mass, loading, route switching, and QT effects correctly.

08

Manage triazoles as both interaction perpetrators and victims across initiation and discontinuation.

09

Join concentration, organ function, electrophysiology, and reproductive context to an action plan.

10

Verify microbiology, source, exposure, response, transition, and long-term ownership as one system.

180.01

Lesson

Read the Azole Target and Pharmacophore

Systemic azoles inhibit fungal lanosterol 14 alpha demethylase, disrupting ergosterol synthesis rather than binding ergosterol directly.

What to learn
  • CYP51
  • Heme coordination
  • Ergosterol depletion
  • Triazole selectivity
  • Resistance
Systemic azole mapInterrupt ergosterol synthesis
01Azole ringDefine the input

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

02CYP51 hemeProtect the conversion

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

03Sterol shiftMeasure the state

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

04Membrane failureOwn the next action

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

Locate the molecular target

An azole nitrogen coordinates the heme iron of fungal CYP51. Hydrophobic regions occupy the substrate channel, while agent-specific substituents shape affinity, spectrum, disposition, and human CYP effects.

Follow the pathway

CYP51 inhibition reduces ergosterol and accumulates abnormal sterol intermediates. The resulting membrane dysfunction differs from the direct pore-forming action of amphotericin B and the cell-wall action of echinocandins.

Separate selectivity from interaction risk

Triazoles generally improve fungal enzyme selectivity relative to early imidazoles, but clinically important inhibition and metabolism through human CYP enzymes remain highly agent specific.

Build a resistance model

Target alteration or overexpression, efflux, and pathway adaptation can reduce susceptibility. Low exposure can resemble resistance, so formulation, adherence, interactions, concentration, organism, and site belong in the same audit.

Quick check

0 of 1 answered
01Which fungal enzyme is directly inhibited by systemic azoles?
Answer every question to submit.
180.02

Lesson

Choose the Agent, Organism, Site, and Phase

Fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole share a class but not one spectrum, indication set, or compartment role.

What to learn
  • Yeasts
  • Molds
  • Endemic fungi
  • Disease phase
  • Oral ketoconazole
Systemic azole mapDefine the antifungal role
01OrganismDefine the input

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

02SiteProtect the conversion

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

03Disease phaseMeasure the state

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

04HostOwn the next action

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

Do not prescribe by class name

Fluconazole has useful yeast activity but no reliable Aspergillus or Mucorales activity. Mold-active triazoles differ from each other, and susceptibility remains organism specific.

Match the disease phase

Induction, step-down, consolidation, prophylaxis, and chronic suppression require different evidence and exposure. A prophylaxis regimen is not automatically a treatment regimen.

Respect the compartment

CNS, eye, urine, lung, bone, blood, valve, and abscess disease create different delivery and source-control problems. In vitro activity does not prove adequate clinical exposure at every site.

Restrict oral ketoconazole

Current labeling does not support oral ketoconazole for onychomycosis, cutaneous dermatophyte infection, or Candida infection. Systemic use requires a compelling indication, unavailable or intolerable alternatives, and intensive liver and interaction safeguards.

Quick check

0 of 1 answered
01Which statement about fluconazole in suspected invasive aspergillosis is correct?
Answer every question to submit.
180.03

Lesson

Use Fluconazole Reliability Precisely

Fluconazole combines high oral bioavailability with primarily renal elimination, but species, dose, compartment, organ function, and interactions still govern success.

What to learn
  • Oral bioavailability
  • Renal clearance
  • Candida species
  • Step-down
  • QT and liver
Systemic azole mapPreserve reliable exposure
01Oral accessDefine the input

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

02LoadingProtect the conversion

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

03Renal maintenanceMeasure the state

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

04SusceptibilityOwn the next action

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

Use the oral route deliberately

Oral and intravenous exposure is often numerically comparable when gastrointestinal function and adherence are reliable. Vomiting, inability to swallow, and severe disease can still make oral delivery inappropriate.

Separate loading from maintenance

A loading dose rapidly fills the distribution volume, while renal function strongly influences maintenance exposure. Do not reflexively reduce a syndrome-specific loading dose solely because creatinine clearance is low.

Require species context

Candida krusei is intrinsically resistant. Candida glabrata requires susceptibility-guided interpretation, and invasive step-down also requires clinical stability, appropriate source control, and documented response.

Monitor beyond the kidney

Fluconazole can cause liver injury, QT prolongation, severe skin reactions, and clinically important CYP-mediated interactions. Renal elimination does not make it interaction free.

Quick check

0 of 1 answered
01Which Candida species is intrinsically resistant to fluconazole?
Answer every question to submit.
180.04

Lesson

Treat Itraconazole Formulation as the Drug

Conventional capsules, oral solution, and newer enhanced-absorption products differ in exposure and cannot be treated as interchangeable containers.

What to learn
  • Capsules
  • Solution
  • Food and pH
  • Heart failure
  • TDM
Systemic azole mapTreat formulation as the drug
01ProductDefine the input

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

02Food and pHProtect the conversion

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

03ConcentrationMeasure the state

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

04Cardiac safetyOwn the next action

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

Name the complete product

Conventional capsules, oral solution, and enhanced-absorption products differ in bioavailability and approved use. Milligram-for-milligram substitution without review can destabilize exposure.

Teach opposing administration rules

Conventional capsules are taken with a full meal and depend on gastric acidity. Oral solution is taken without food when possible. Acid suppression, gastric surgery, nausea, and tube feeding can change the plan.

Protect the heart

Itraconazole has negative inotropic potential and a boxed warning for congestive heart failure and cardiac effects. New edema, dyspnea, rapid weight gain, or exercise intolerance requires prompt evaluation and treatment reassessment.

Interpret the assay correctly

Variable absorption and active hydroxyitraconazole make concentration monitoring useful. Targets depend on timing, indication, formulation, and whether the laboratory reports parent drug alone or a combined value.

Quick check

0 of 1 answered
01A patient takes conventional itraconazole capsules fasting with a proton pump inhibitor. What is the main concern?
Answer every question to submit.
180.05

Lesson

Control Voriconazole Variability

Voriconazole combines broad mold activity with nonlinear adult pharmacokinetics, CYP2C19 variability, and exposure-linked neurologic, hepatic, cutaneous, and skeletal toxicity.

What to learn
  • Nonlinear PK
  • CYP2C19
  • TDM
  • Visual and CNS effects
  • Long-term toxicity
Systemic azole mapControl nonlinear variability
01DoseDefine the input

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

02TroughProtect the conversion

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

03CYP2C19Measure the state

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

04ToxicityOwn the next action

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

Respect nonlinearity

Adult metabolism is saturable, so a dose increase can cause a disproportionate concentration rise. Incremental adjustment and repeat TDM are safer than assuming a linear dose-to-level relationship.

Measure the individual

CYP2C19 phenotype, inflammation, liver function, age, and interacting drugs contribute to variability. A correctly timed concentration is more actionable than guessing metabolism from demographic characteristics.

Classify early toxicity

Transient visual disturbance is common, while hallucinations, confusion, severe visual symptoms, or other CNS effects can signal excessive exposure or another urgent cause. Counsel about night driving and reassess symptoms promptly.

Plan for cumulative toxicity

Prolonged therapy can produce photosensitivity, cutaneous malignancy, periostitis, and fluorosis. Sun protection, skin surveillance, bone-symptom review, laboratory assessment, and continuing-need review evolve with duration.

Quick check

0 of 1 answered
01Why should a low voriconazole trough not automatically trigger a doubled dose?
Answer every question to submit.
180.06

Lesson

Make Posaconazole Formulation Visible

Delayed-release tablets, oral suspension, and PowderMix differ in indication, eligibility, dosing, preparation, and exposure.

What to learn
  • Delayed-release tablet
  • Oral suspension
  • Non-substitution
  • Food
  • Pseudoaldosteronism
Systemic azole mapChoose product before dose
01FormulationDefine the input

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

02AdministrationProtect the conversion

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

03ExposureMeasure the state

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

04ElectrolytesOwn the next action

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

Stop unsafe substitution

Posaconazole formulations are explicitly non-substitutable. A product switch requires a new indication, eligibility, dose, administration, and monitoring verification rather than a copied milligram amount.

Use the current tablet instruction

Delayed-release tablets are swallowed whole and may be taken with or without food. This differs from older generalized teaching that every posaconazole dose must accompany a meal.

Protect suspension absorption

Oral suspension is given with a full meal or, when needed, a nutritional supplement or acidic carbonated beverage. Poor intake, acid suppression, mucositis, diarrhea, and tube feeding can undermine exposure.

Recognize mineralocorticoid excess

Hypertension, hypokalemia, and metabolic alkalosis can signal posaconazole-associated pseudoaldosteronism. Blood pressure, potassium, bicarbonate, exposure, renin, aldosterone, and competing causes guide evaluation.

Quick check

0 of 1 answered
01Can posaconazole delayed-release tablets and oral suspension be substituted at the same milligram dose?
Answer every question to submit.
180.07

Lesson

Translate Isavuconazonium Without Error

Isavuconazonium is a water-soluble prodrug whose active-equivalent mass, loading sequence, route equivalence, interactions, and QT shortening require precise translation.

What to learn
  • Prodrug
  • Active equivalent
  • Loading
  • Route switch
  • QT shortening
Systemic azole mapTranslate prodrug to active exposure
01Prodrug massDefine the input

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

02LoadingProtect the conversion

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

03Route switchMeasure the state

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

04QT directionOwn the next action

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

Read both mass conventions

A 372 mg dose of isavuconazonium sulfate is equivalent to 200 mg of active isavuconazole. Orders, labels, handoffs, and calculations must state the intended convention clearly.

Complete the adult loading sequence

Adult treatment uses 372 mg every 8 hours for six doses, then 372 mg once daily. Maintenance begins 12 to 24 hours after the last loading dose.

Switch routes without resetting exposure

Oral and intravenous formulations are bioequivalent. A verified route change continues the schedule and does not automatically restart all six loading doses.

Distinguish QT direction

Isavuconazole shortens QT in a concentration-related manner and is contraindicated in familial short QT syndrome. QT direction alone does not erase interaction, liver, or patient-specific risk.

Quick check

0 of 1 answered
01How much active isavuconazole is equivalent to 372 mg of isavuconazonium sulfate?
Answer every question to submit.
180.08

Lesson

Own the Interaction From Start Through Stop

Triazoles can inhibit CYP enzymes, depend on them for clearance, encounter strong induction, and alter electrophysiologic risk.

What to learn
  • Perpetrator
  • Victim
  • Induction
  • QT burden
  • Offset
Systemic azole mapOwn the interaction lifecycle
01StartDefine the input

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

02Steady stateProtect the conversion

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

03StopMeasure the state

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

04Follow-upOwn the next action

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

Review both directions

A triazole may raise a narrow-therapeutic-index substrate while another drug changes triazole exposure. Build the interaction map before the first dose rather than reacting to a late concentration.

Treat strong induction as failure risk

Rifamycins, selected anticonvulsants, St John's wort, and other strong inducers can collapse mold-active triazole exposure. Avoid contraindicated combinations or redesign therapy with specialist support.

Calculate the full QT system

Several triazoles can prolong QT, while isavuconazole shortens it. QTc, congenital syndromes, heart rate, structural disease, potassium, magnesium, calcium, and every co-medication determine the actual risk.

Plan the interaction offset

A substrate dose reduced when an azole starts may become subtherapeutic when inhibition resolves after discontinuation. Document the responsible clinician, monitoring schedule, and dose-reassessment trigger for both directions.

Quick check

0 of 1 answered
01Tacrolimus was reduced when voriconazole began. What must be planned when voriconazole stops?
Answer every question to submit.
180.09

Lesson

Turn Every Measurement Into an Action

Concentration, liver, kidney, electrolyte, ECG, skin, vision, bone, and reproductive assessments become useful only when timing and action thresholds are defined.

What to learn
  • TDM
  • Liver
  • Kidney and vehicle
  • Electrolytes and ECG
  • Pregnancy and lactation
Systemic azole mapMeasure only with an action
01QuestionDefine the input

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

02TimingProtect the conversion

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

03ResultMeasure the state

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

04ResponseOwn the next action

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

Use TDM where variability matters

Itraconazole and voriconazole have especially compelling exposure variability. Posaconazole and other agents may also need concentrations when delivery, interaction, failure, or toxicity questions can change management.

Monitor the liver dynamically

Every systemic triazole can cause clinically important liver injury. Baseline tests do not prevent later injury, so symptoms, duration, hepatic function, co-medications, and trend determine the surveillance interval.

Separate kidney mechanisms

Fluconazole maintenance exposure depends strongly on renal clearance. Selected intravenous formulations raise separate concerns about a solubilizing vehicle. Do not apply one renal rule to every active drug and product.

Use current reproductive information

Pregnancy and lactation decisions require current agent-specific narrative labeling, dose, route, duration, disease severity, alternatives, and specialist input. Obsolete pregnancy letters are not an adequate decision system.

Quick check

0 of 1 answered
01Which situation most strongly supports triazole TDM?
Answer every question to submit.
180.10

Lesson

Close the Triazole Clinical Loop

Successful therapy joins diagnosis, organism, site, source, exact product, exposure, toxicity, response, transition, and long-term ownership.

What to learn
  • Baseline
  • Breakthrough audit
  • Step-down
  • Longitudinal safety
  • Educational boundary
Systemic azole mapClose the triazole loop
01VerifyDefine the input

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

02DeliverProtect the conversion

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

03MonitorMeasure the state

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

04TransitionOwn the next action

Keep target, formulation, exposure, organism, toxicity, and ownership connected.

Verify the baseline

Confirm syndrome, host, organism evidence, susceptibility, site, source, exact product, dose, administration, organ function, interactions, ECG and electrolytes when relevant, reproductive context, and monitoring owner.

Audit breakthrough broadly

Wrong organism, resistance, poor absorption, formulation error, interaction, nonadherence, inadequate dose, uncontrolled source, and limited site exposure can all create failure. Do not equate breakthrough with resistance alone.

Require step-down readiness

Clinical stability, source control, susceptible organism, active oral agent, reliable formulation exposure, manageable interactions, and follow-up must all be secured before a high-risk transition.

Update the long-term plan

Duration changes the toxicity field. Medication reconciliation, liver tests, ECG and electrolytes, skin and vision review, bone symptoms, heart failure, blood pressure, concentrations, and continuing need evolve over time.

Quick check

0 of 1 answered
01What is the best first response to breakthrough mold infection during posaconazole suspension prophylaxis?
Answer every question to submit.

Module test

Check the connections.

Each attempt draws 10 questions from the complete 176 question bank.

176 questions in this module bank10 questions per attempt

Each attempt draws a fresh set and rearranges the answer choices.

References

Current clinical foundation.

Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.

  1. DailyMed Fluconazole Label, updated 2025
  2. DailyMed Itraconazole Capsule Label
  3. DailyMed Itraconazole Oral Solution Label
  4. DailyMed Voriconazole Label, updated 2025
  5. DailyMed Posaconazole Label, updated 2026
  6. DailyMed Cresemba Label
  7. DailyMed Oral Ketoconazole Label
  8. IDSA Aspergillosis Guideline
  9. IDSA Candidiasis Guideline
  10. IDSA Histoplasmosis Guideline, 2025
PharmacyOpen tools